Morgan Stanley is an American multinational investment bank and financial services firm. Founded in 1935 and headquartered in New York City, it operates globally across investment banking, wealth management, and institutional securities. The company is publicly traded on the NYSE under MS.
West Pharmaceutical Services beat Q2 estimates with revenue of $872.3 million and raised full-year guidance, driven by GLP-1 and high-value product demand. The stock is up 32.9% year to date, and Wolfe Research upgraded the shares to Outperform with a $375 price target.
AbbVie has received a "Moderate Buy" consensus rating from analysts with an average price target of $253.15. The company reported strong quarterly earnings of $2.71 EPS and $16.62 billion revenue, beating estimates. Recent clinical progress includes positive Phase 1 results for an obesity drug candidate showing 7.8-9.8% weight loss.
Morgan Stanley raised its Novartis price target to $170 from $143 with an Overweight rating, while TD Cowen increased its target to $180 from $160 with a Hold rating. Morgan Stanley sees $23 billion in risk-adjusted potential from nine pipeline assets, with additional upside in success scenarios.
Multiple institutional investors expanded their positions in AstraZeneca during the third quarter of 2025, with several funds increasing holdings by over 100% according to SEC filings.
Analysts updated ratings on healthcare stocks: Ultragenyx remains Strong Buy, Immutep downgraded to Hold, BridgeBio gets Buy. American Well and Baxter stay Hold. Upside ranges from 11% to 154%.
Johnson & Johnson stock hit an all-time high of $246.54, up 54.05% over the past year. The company announced a $1 billion investment in a Pennsylvania cell therapy facility and received upgraded price targets from major financial firms.
Medtronic's diabetes unit MiniMed is seeking up to $7.86 billion valuation in its U.S. IPO while cutting 81 jobs at its Northridge facility ahead of the planned separation into a standalone publicly traded company.
FDA Commissioner Marty Makary identified hospital contracting, IRB processes, and IND application timelines as key bottlenecks slowing US early-phase trials. China now conducts more clinical trials than the US and accounts for nearly a third of new global drug approvals.
Two financial services firms raised their price targets for Moderna in mid-February 2026, with RBC Capital increasing its target to $30 and Evercore ISI Group raising its target to $35, both maintaining neutral ratings.
Multiple institutional investors modified their positions in AstraZeneca during the third quarter, with new stakes and adjustments reported in SEC filings. The company announced a dividend of $1.595 per share payable March 23rd.
